# Amplion Clinical Communications, Inc. - Inspection Records

Source: https://www.globalkeysolutions.net/companies/amplion-clinical-communications-inc/9de142e5-9171-405f-bf2c-890e2a0b5f93

> Inspection records and compliance data for Amplion Clinical Communications, Inc. in Nashville, Tennessee. Access full analysis and detailed observations.

---

## Details

- Name: Amplion Clinical Communications, Inc.
- FEI Number: 3009164985
- City: Nashville
- State: Tennessee
- Country Name: United States
- Address Line 1: 632 Melrose Ave
- Zip Code: 37211

## Related Documents

- [483 - Amplion Clinical Communications, Inc. - 2023-02-16](https://www.globalkeysolutions.net/records/483/amplion-clinical-communications-inc/27985aa0-8863-44d5-84cb-338c12fac6a8) — source: FDA, date: February 16, 2023
- [FDA Inspection 1199005 - Amplion Clinical Communications, Inc. - 2023-02-16](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/dc4e1f97-7b96-49d1-95e1-ff4d4626cb43) — classification: No Action Indicated (NAI), source: FDA, date: February 16, 2023
- [FDA Inspection 1199005 - Amplion Clinical Communications, Inc. - 2023-02-16](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/d08eec81-acd0-4609-9dac-a657fdf89adb) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 16, 2023
- [483 - Amplion Clinical Communications, Inc. - 2021-09-08](https://www.globalkeysolutions.net/records/483/amplion-clinical-communications-inc/389d4dd7-6f9d-4e81-8575-4b9e65878dea) — source: FDA, date: September 8, 2021
- [FDA Inspection 1151083 - Amplion Clinical Communications, Inc. - 2021-09-08](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/376230bf-ac49-414c-ac3a-1d63f8bafb0f) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 8, 2021
- [483 - Amplion Clinical Communications, Inc. - 2019-09-04](https://www.globalkeysolutions.net/records/483/amplion-clinical-communications-inc/b54e3be6-5d11-49b1-b39e-69cbf9f2b3c6) — source: FDA, date: September 4, 2019
- [FDA Inspection 1101295 - Amplion Clinical Communications, Inc. - 2019-09-04](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/85eda264-7d18-4ae8-bbd2-4abbb625a3c6) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 4, 2019
- [FDA Inspection 1101295 - Amplion Clinical Communications, Inc. - 2019-09-04](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/8d9981c0-bc81-4ebc-b4a6-f824168c89b0) — classification: No Action Indicated (NAI), source: FDA, date: September 4, 2019
- [FDA Inspection 1024360 - Amplion Clinical Communications, Inc. - 2017-09-07](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/c77efe9a-9bc2-4b7d-8c91-8b3f14ca632c) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 7, 2017
- [FDA Inspection 1024360 - Amplion Clinical Communications, Inc. - 2017-09-07](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/9b2a4de4-ecd0-43f5-a382-a5dfc11920dc) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 7, 2017
- [FDA Inspection 881285 - Amplion Clinical Communications, Inc. - 2014-06-05](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/333e7e01-dfa2-44bf-9807-b2011f023662) — classification: No Action Indicated (NAI), source: FDA, date: June 5, 2014
- [FDA Inspection 881285 - Amplion Clinical Communications, Inc. - 2014-06-05](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/bd55883d-9e28-4ef1-8cde-36593e8443c4) — classification: No Action Indicated (NAI), source: FDA, date: June 5, 2014
- [FDA Inspection 854307 - Amplion Clinical Communications, Inc. - 2013-11-04](https://www.globalkeysolutions.net/records/fda_inspections/amplion-clinical-communications-inc/8e29d9ee-10bc-4205-99ae-ff36b8c74aa7) — classification: Official Action Indicated (OAI), source: FDA, date: November 4, 2013

## Related Companies

- [Intuitive Surgical, Inc.](https://www.globalkeysolutions.net/companies/intuitive-surgical-inc/2dea1052-5e1b-4f51-b3e3-6792452d36de)
- [Abaxis Inc](https://www.globalkeysolutions.net/companies/abaxis-inc/98392f88-354f-4be2-b781-a75f289470a2)
- [American National Red Cross, Penn Jersey Region](https://www.globalkeysolutions.net/companies/american-national-red-cross-penn-jersey-region/7d2928f2-8d2a-48db-b0df-6c8a10016030)
- [Emcure Pharmaceuticals Limited](https://www.globalkeysolutions.net/companies/emcure-pharmaceuticals-limited/f9f57aff-9896-431c-b393-98180a923777)
- [Integra LifeSciences Corporation](https://www.globalkeysolutions.net/companies/integra-lifesciences-corporation/cd77e730-dc06-470e-ae7b-58c860df5c29)
- [Reproductive Technologies, Inc.](https://www.globalkeysolutions.net/companies/reproductive-technologies-inc/81a46c28-125d-4e9e-ba8b-1d521dff2b44)
- [Advanced Instrumentations, Inc.](https://www.globalkeysolutions.net/companies/advanced-instrumentations-inc/4d9b9f1e-df18-4b76-ba69-fbb66b575fc4)
- [Neuronetrix Solutions, LLC](https://www.globalkeysolutions.net/companies/neuronetrix-solutions-llc/0d8ea998-36a4-47ea-9061-2b9c227fded5)
- [AMCO International Manufacturing & Design, Inc.](https://www.globalkeysolutions.net/companies/amco-international-manufacturing-design-inc/d83d67ac-3fc8-49f1-b009-258ee8b8681a)
- [California IVF Fertility Center](https://www.globalkeysolutions.net/companies/california-ivf-fertility-center/c2670fe5-c56f-4d8a-b7e6-6bec4a2a8035)

## Related Officers

- [Mary A. Millner](https://www.globalkeysolutions.net/people/mary-a-millner/bd8911cf-849d-41d2-ae12-dd4bad66e798)
- [investigator](https://www.globalkeysolutions.net/people/nikki-s-bryant/fe859d4f-23a6-4bc9-94c6-5b3c3fe8d99a)
- [Benjamin E. Bowen](https://www.globalkeysolutions.net/people/benjamin-e-bowen/7fdc5755-0d5d-45c9-93a0-3cb928156c1d)